Poland· PL-100463978
Novain
A oxybuprocaine product containing oxybuprocaini hydrochloridum, registered in Poland by AGEPHA Pharma s.r.o.. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Oxybuprocaine is registered in 11 of 19 countries.
Countries holding a registration under ATC S01HA02 (oxybuprocaine), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Oxybuprocaine · ATC S01HA02
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
URPL (Poland)- Active substance
- Oxybuprocaini hydrochloridum
- Manufacturer
- AGEPHA Pharma s.r.o.
- Country
- Poland (PL)
- ATC code
- S01HA02
- ATC class
- Oxybuprocaine
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991516765
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
40 interactions on record for oxybuprocaine.
Graded by severity as the source publishes them — 40 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Oxybuprocaine · interactions on record
40 records
- 40 moderate
Most severe, free to view
- MetoclopramideA03FA01moderate
- SulfamethizoleB05CA04moderate
- LidocaineC01BB01moderate
- Glyceryl trinitrateC01DA02moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Oxybuprocaine in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandMinims Oxybuprocaine HydrochlorideBausch + Lomb Ireland Limited
- SwedenObupro 4 mg/ml Ögondroppar, lösningAgepha Pharma s.r.o.
- CzechiaBENOXIUNIMED PHARMA spol. s r.o., Bratislava
- NetherlandsMinims Oxybuprocainehydrochloride 4 mg/ml, oogdruppels, oplossingBausch + Lomb Ireland Limited
- NorwayOxibuprokain MinimsBAUSCH + LOMB IRELAND LIMITED
- IrelandOxybuprocaine Agepha 4 mg/ml eye drops, solutionAGEPHA Pharma s.r.o.
- FranceCHLORHYDRATE D'OXYBUPROCAINE THEA 1,6 mg/0,4 ml, collyre en récipient unidoseTHEA
- BelgiumMinims Oxybuprocaine Chlorhydrate 4 mg/mlBausch + Lomb Ireland
Authorised across Europe · EMA
The same active substance is authorised in 25 EEA countries. Names it is sold under:
- Austria · Benoxinat Zur Anästhesie In Der Oto-Rhino-Laryngologie, Novain
- Belgium · Minims Oxybuprocaine Chlorhydrate Bausch + Lomb Ireland Limited, Minims Oxybuprocaïnehydrochloride Bausch + Lomb Ireland Limited
- Bulgaria · Бенокси
- Czechia · Benoxi, Oxybuprocaine Olikla
- Germany · Conjuncain® Edo®, Novesine
- Denmark · Oftasen, Oxybuprocainhydrochlorid Agepha
- Estonia · Novain
- Spain · Oxibuprocaína Hidrocloruro Agepha
- Finland · Minims, Obupro 4 Mg/Ml Silmätipat, Liuos
- France · Cebesine, Chlorhydrate D’oxybuprocaine Thea
- United Kingdom (Northern Ireland) · Oxybuprocaine Hydrochloride Alfa Intes
- Croatia · Ophtesia
- Hungary · Humacain, Oxybuprocaine Hydrochloride Agepha
- Ireland · Oxybuprocaine Agepha
- Iceland · Novain
- Italy · Benoxinato Cloridrato Intes, Novesina
- Lithuania · Novain
- Luxembourg · Conjuncain Edo, Minims
- Latvia · Oxybuprocaine Hydrochloride Agepha 4 Mg/Ml
- Netherlands · Minims, Monofree
- Norway · Obupro, Oxibuprokain Minims Bausch + Lomb Ireland Limited
- Portugal · Anestocil, Novain 4 Mg/Ml Colírio,
- Romania · Benoxi, Oftacain
- Sweden · Novain, Oxibuprokain Bausch & Lomb
- Slovakia · Benoxi, Oxybuprocaine Olikla
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b6e66d84-158b-47d0-a024-e6f8c4d3c9e4 GET /v1/drugs/b6e66d84-158b-47d0-a024-e6f8c4d3c9e4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Krople do oczu, roztwór",
"source": "urpl",
"strength": "4 mg/ml",
"packaging": "05909991516765 ¦ Rpz ¦ 150435\n1 butelka 10 ml",
"substance": "Oxybuprocaini hydrochloridum 4 mg/ml",
"common_name": "Oxybuprocaini hydrochloridum",
"pl_product_id": "100463978",
"pozwolenie_nr": "27901",
"auth_procedure": "MRP",
"authorisation_validity": "2028-06-29"
}See everything about oxybuprocaine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.